Amgen to Present 10 Abstracts from its Dermatology Portfolio at the 73rd Annual Meeting of the AAD

Amgen will present data from multiple brodalumab and Enbrel (etanercept) studies at the 73rd Annual Meeting of the American Academy of Dermatology (AAD) in San Francisco, 20–24 March 2015. The breadth of data to be presented highlights Amgen's long-term commitment to advancing innovative treatment options for patients with serious, chronic dermatologic diseases.

"Patients with psoriasis struggle on a daily basis with the serious symptoms of the disease, and we are excited to share research findings at this year's AAD meeting that highlight our continued commitment to advancing science to help these patients," said Sean E. Harper, executive vice president of R&D at Amgen. "Results from our Phase III brodalumab clinical trial program draw on research from more than 4200 patients and provide important insights on safety and efficacy of this IL-17 receptor inhibitor in moderate-to-severe plaque psoriasis, while new Enbrel data offer perspectives on use and adherence in a real-world setting."

Data to be presented include results from all three of the brodalumab Phase III Amagine pivotal trials, evaluating the efficacy and safety of the IL-17 receptor inhibitor in patients with moderate-to-severe plaque psoriasis from the induction through the maintenance phase through week 52. Additional brodalumab long-term data from the Phase 2IIopen-label extension study provide further insights on the maintenance of clinical response with long-term brodalumab therapy in patients with moderate-to-severe psoriasis. Brodalumab is being co-developed by Amgen and AstraZeneca.

Kyowa Hakko Kirin, which has an exclusive licence to develop and commercialise brodalumab in Japan, China and certain other Asian countries, will present additional, long-term Phase III brodalumab efficacy and safety data from its open-label extension study in Japanese patients with moderate-to-severe plaque psoriasis.

Enbrel data provide insights from OBSERVE-5, an observational registry designed to examine the use of Enbrel in a real-world setting over five years, as well as on treatment patterns with Enbrel compared with other agents in US veterans with moderate-to-severe plaque psoriasis and psoriatic arthritis.

Additional data to be presented will look at patient-reported psoriasis symptom severity using the Psoriasis Symptom Inventory (PSI) scale compared to Physician Global Assessment results.